THALES
10.4.2024 11:40:33 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced a collaboration leveraging its CipherTrust Data Security Platform (CDSP) to support End-To-End Data Protection (E2EDP) on Google Cloud, using Confidential Computing (CC) from Google Cloud and trusted cloud independent attestation provided by Intel Trust Authority (ITA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410848317/en/
©Thales
The effort is a step forward in data security, giving enterprises additional controls to protect their data at rest, in transit, and in use.
“As more enterprises migrate their data and workloads to the cloud, there is an increasing demand to safeguard the privacy and integrity of the data, especially those sensitive workloads that include intellectual property, AI models and valuable personal information. This collaboration enables enterprises to protect and control their data at rest, in transit and in use with fully verifiable attestation. Our close collaboration with Google Cloud and Intel increases our customers' trust in their cloud migration,” said Todd Moore, Vice President of Data Security Products at Thales.
A majority of the 2023 Thales Cloud Security Study respondents reported having a significant amount of sensitive data stored and in use in the cloud. Consequently, safeguarding sensitive data and associated workloads when stored or in use, is an increasing priority, especially for highly regulated industries such as financial services and healthcare. Thales's collaboration with Intel and Google Cloud provides certifiable controls for enterprises to fully protect their data end-to-end.
Purnam Sheth, Vice President and General Manager: Trust and Security Products, SATG at Intel: “Creating this groundbreaking, seamless data security platform in Google Cloud meets customers’ complex requirements for data protection, controlled access and security, and adherence to compliance for data at rest, in transit and in use. Foundational Intel® Trust Domain Extensions Confidential Compute and Intel® Trust Authority gives enterprises assurance of the integrity of their workloads and guards at all stages of data management. This valuable collaboration between Thales, Google Cloud and Intel makes this possible.”
This security platform is based on the principle of separation of duties, where the customer remains in control of the encryption keys and their location. This approach enhances trust by holding each stakeholder responsible for their respective roles and reduces the ability for a malicious actor to access code and data at rest, in transit and while being executed.
Customers can migrate existing workloads with sensitive data or create new workloads needing zero trust, confidential computing and Confidential AI to this security platform in Google Cloud to broaden data security, attestation and set the right authorizations. With end-to-end data protection, multiple parties can securely collaborate on various use cases, such as Confidential AI datasets and models as needed while preserving privacy, confidentiality, and compliance with privacy regulations.
The Thales CipherTrust Data Security Platform uses Intel Trust Authority as a zero-trust, independent attestation service for advanced security and scalable confidential computing. Consistent attestation to Trusted Execution Environments (TEE) that are based on Intel Trust Domain Extensions. This single, consistent attestation process provides assurance to any relying party that the TEE and any data and workloads running within it have not been compromised.
Brian Roddy, VP, Product Management, Google Cloud: “Google Cloud is committed to providing our customers secure, private and reliable environments for their workloads, and our Confidential Computing portfolio plays a critical role in this effort. Offering our customers solutions like Thales’ encryption key management expertise, combined with Intel’s Trust Authority attestation, enables the choice of even stronger privacy controls.”
The collaboration comes as Thales is recognized for its achievements in the Google Cloud ecosystem. For the second year in a row, Thales has received the 2024 Google Cloud Technology Partner of the Year Award for Security - Data Protection.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Artificial Intelligence, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410848317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
